At 15,908 points, the leading German index was little changed at the opening on Tuesday. Over the course of the day, investors are focusing on the minutes of the latest interest rate meeting of the US Federal Reserve. Investors are hoping that the transcripts of internal discussions will provide clues as to the future course of monetary policy.

The previous day, an 18% fall in the price of Bayer shares weighed on the German stock market. "Without the Bayer losses, the DAX could have gained for the 6th day in a row yesterday," said portfolio manager Thomas Altmann from asset manager QC Partners. "We see that investors are now taking a wait-and-see approach after the long winning streak."

Meanwhile, Morphosys shares plummeted by around 30 percent. The biotech company had presented the results of the decisive study with its most promising drug Pelabresib the previous evening. Morphosys had demonstrated a statistically significant benefit for the primary endpoint, but no clinically meaningful benefit for the most important secondary endpoint, said a trader.

(Report by Stefanie Geiger, edited by Hans Busemann. If you have any questions, please contact our editorial team at berlin.newsroom@thomsonreuters.com (for politics and the economy) or frankfurt.newsroom@thomsonreuters.com (for companies and markets)